- Promethera, a Belgian stem-cell medicine development company, announces the result of HepaStem’s Europe clinical phase 2a (aimed at patients with Acute-on-chronic liver failure (ACLF)) at American Associationfor the Study of Liver Diseases (AASLD) holding in Boston from November 8th to 12th.
- The following clinic was individually progressed by Promethera in Europe and evaluated the safety and efficacy of HepaStem.
- HepaStem is a liver-derived stem cell developed by Promethera and Lifeliver Inc. (an affiliated company of HLB Life Science) owns a domestic copyright.